Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

758 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients with HIV.
Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez-Sousa MA, López JC, Pinto-Martínez A, Moreno S, Montes ML, Iribarren JA, Orviz E, Portilla J, Villarroya F, Domingo P, Resino S; CoRIS cohort. Berenguer J, et al. Among authors: domingo p. J Infect Dis. 2024 Apr 1:jiae168. doi: 10.1093/infdis/jiae168. Online ahead of print. J Infect Dis. 2024. PMID: 38557859
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).
Podzamczer D, Micán R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masiá M, Gómez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro Á, Bernal E, Vinuesa D, Knobel H, Troya J, Macías J, Montero M, Sanz J, Navarro-Alcaraz A, Caicedo A, Fernández G, Martínez E, Moreno S. Podzamczer D, et al. Among authors: domingo p. Open Forum Infect Dis. 2021 Nov 25;9(3):ofab595. doi: 10.1093/ofid/ofab595. eCollection 2022 Mar. Open Forum Infect Dis. 2021. PMID: 35237700 Free PMC article.
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group. Arribas JR, et al. Among authors: domingo p. Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062880 Clinical Trial.
Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics.
Berenguer J, Rivero A, Jarrín I, Núñez MJ, Vivancos MJ, Crespo M, Téllez MJ, Domingo P, Iribarren JA, Artero A, Márquez M, Santos I, Moreno J, Montero M, González-García J. Berenguer J, et al. Among authors: domingo p. Open Forum Infect Dis. 2016 Mar 11;3(2):ofw059. doi: 10.1093/ofid/ofw059. eCollection 2016 Mar. Open Forum Infect Dis. 2016. PMID: 27186584 Free PMC article.
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, Knobel H, Rivero A, Alejos B, Yllescas M, Arribas JR; DUAL-GESIDA-8014-RIS-EST45 Study Group. Pulido F, et al. Among authors: domingo p. Clin Infect Dis. 2017 Nov 29;65(12):2112-2118. doi: 10.1093/cid/cix734. Clin Infect Dis. 2017. PMID: 29020293 Clinical Trial.
Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant.
Berenguer J, Jarrín I, Pérez-Latorre L, Hontañón V, Vivancos MJ, Navarro J, Téllez MJ, Guardiola JM, Iribarren JA, Rivero-Juárez A, Márquez M, Artero A, Morano L, Santos I, Moreno J, Fariñas MC, Galindo MJ, Hernando MA, Montero M, Cifuentes C, Domingo P, Sanz J, Domíngez L, Ferrero OL, De la Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, Losa JE, Vilaró J, Bernal E, Arponen S, Ortí AJ, Chocarro Á, Teira R, Alonso G, Silvariño R, Vegas A, Geijo P, Bisbe J, Esteban H, González-García J; GeSIDA 8514 Study Group. Berenguer J, et al. Among authors: domingo p. Open Forum Infect Dis. 2018 Jan 12;5(1):ofx258. doi: 10.1093/ofid/ofx258. eCollection 2018 Jan. Open Forum Infect Dis. 2018. PMID: 29354658 Free PMC article.
A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes.
Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce-Pardeiro N, Payeras A, Bernal E, Montero-Alonso M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R. Santos JR, et al. Among authors: domingo p. Open Forum Infect Dis. 2023 Oct 31;10(11):ofad542. doi: 10.1093/ofid/ofad542. eCollection 2023 Nov. Open Forum Infect Dis. 2023. PMID: 38023553 Free PMC article.
Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, Pulido F, Rubio R, Santos J, de la Torre J, Tuset M, Gatell JM. Rivero A, et al. Among authors: domingo p. Enferm Infecc Microbiol Clin (Engl Ed). 2018 May;36(5):268-276. doi: 10.1016/j.eimc.2017.04.002. Epub 2017 May 19. Enferm Infecc Microbiol Clin (Engl Ed). 2018. PMID: 28532596 English, Spanish.
758 results